# A Study of ASP1570 Taken by Itself, or ASP1570 Taken Together With Either Pembrolizumab, Standard Therapies, or Both, in Adults With Solid Tumors

> **NCT05083481** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Astellas Pharma Global Development, Inc.** · enrollment: 226 (actual)

## Conditions studied

- Advanced Solid Tumors

## Interventions

- **DRUG:** ASP1570
- **DRUG:** pembrolizumab
- **DRUG:** Trifluridine + Tipiracil
- **DRUG:** Bevacizumab
- **DRUG:** Docetaxel
- **DRUG:** Oxaliplatin
- **DRUG:** Leucovorin
- **DRUG:** 5-Fluorouracil
- **DRUG:** Irinotecan
- **DRUG:** Pemetrexed
- **DRUG:** Carboplatin

## Key facts

- **NCT ID:** NCT05083481
- **Lead sponsor:** Astellas Pharma Global Development, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-10-19
- **Primary completion:** 2026-06-30
- **Final completion:** 2026-06-30
- **Target enrollment:** 226 (ACTUAL)
- **Last updated:** 2026-05-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05083481

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05083481, "A Study of ASP1570 Taken by Itself, or ASP1570 Taken Together With Either Pembrolizumab, Standard Therapies, or Both, in Adults With Solid Tumors". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05083481. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*